GlassScriptPhysician profile
John D Douthit
NPI 1144304767
$2,910.99
in general payments reported to CMS, 2019-2025
26 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $298 · 2021: $455 · 2022: $304 · 2023: $375 · 2024: $519 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $834.04 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $515.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $296.96 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $148.40 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $116.07 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.92 | 2021-2025 | |
| Pfizer INC. | $90.57 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.54 | 2020-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.23 | 2019-2024 | |
| Novo Nordisk INC | $82.63 | 2019-2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $79.62 | 2024-2025 | Rexulti |
| Gilead Sciences, INC. | $65.98 | 2019-2025 | |
| Amarin Pharma, INC. | $57.48 | 2019-2020 | |
| Allergan, INC. | $46.30 | 2019-2020 | |
| Eisai INC. | $43.62 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $32.86 | 2024-2025 | Opsumit, Uptravi |
| Verona Pharma, INC. | $28.60 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $26.98 | 2021-2023 | Veozah |
| Exact Sciences Corporation | $26.74 | 2025 | Cologuard Collection Kit |
| Cequr Corporation | $23.35 | 2024 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $23.18 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.91 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $16.29 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $14.58 | 2019 | |
| Shire North American Group INC | $12.99 | 2019 | |
| Abbott Laboratories | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Douthit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.